Surmodics INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
SRDX
Surmodics INCSurmodics, Inc. has filed a definitive proxy statement with the SEC in preparation for its upcoming shareholder meeting.
SRDX
Surmodics INCSurmodics, Inc. has scheduled its annual shareholder meeting for February 6, 2025, as a virtual event, while also navigating a pending merger agreement.
SRDX
Surmodics INCSurmodics and BCE Parent, LLC receive a second request for information from the FTC, extending the waiting period for their merger, but still anticipate closing the deal by February 28, 2025.
SRDX
Surmodics INCSurmodics, Inc. has entered into a definitive agreement to be acquired by an entity indirectly controlled by GTCR LLC for $43.00 per share in cash.
SRDX
Surmodics INCSurmodics has entered into a definitive agreement to be acquired by GTCR, a private equity firm, for $43.00 per share in cash, valuing the company at approximately $627 million.
SRDX
Surmodics INCSurmodics, Inc. has entered into a definitive agreement to be acquired by GTCR for $43.00 per share in cash, representing an approximate equity value of $627 million.